You just read:

Atrin Pharmaceuticals Awarded $300,000 Phase 1 Contract for Development of Highly Specific ATR inhibitors for Targeted Cancer Treatment

News provided by

Atrin Pharmaceuticals, Inc.

Oct 19, 2016, 08:30 ET